share_log

Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know

Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know

来自Arcus Biosciences分析师评级的关键见解:你需要知道的
Benzinga ·  02/22 09:00
Throughout the last three months, 4 analysts have evaluated Arcus Biosciences (NYSE:RCUS), offering a diverse set of opinions from bullish to bearish.
在过去的三个月中,有4位分析师对Arcus Biosciences(纽约证券交易所代码:RCUS)进行了评估,提供了从看涨到看跌的不同观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表总结了他们最近的评估,说明了过去30天不断变化的情绪,并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.5, a high estimate of $42.00, and a low estimate of $30.00. This current average represents a 20.69% decrease from the previous average price target of $43.50.
在对12个月目标股价的评估中,分析师公布了对Arcus Biosciences的见解,平均目标股价为34.5美元,最高估计为42.00美元,低估值为30.00美元。目前的平均价格比之前的平均目标价43.50美元下降了20.69%。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析师评级:详细审查
The standing of Arcus Biosciences among financial experts becomes...
通过对分析师近期行...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发